Viewing nowCombinationEmpamax M Sustained Release Tablet 25/1000 mg (Empagliflozin, Metformin)
Empagliflozin L-Proline 31.38mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.

MFDS item code 202501899 · Approved 2025.07.24 · Insurance code 643310010
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps improve blood sugar control in adult patients with type 2 diabetes who have not achieved adequate control with diet and exercise. Caution should be taken in patients at risk for cardiovascular disease, and detailed information regarding cardiovascular events can be referenced in clinical trial information for professionals. This medication is used to enhance blood sugar control in adult patients with type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Patients taking this medicine as 10/1000 mg or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/1000 mg or 12.5/750 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medicine should be swallowed whole without splitting, crushing, grinding, or chewing. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose of this medicine is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this medicine should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dosage adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dosage adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with metformin hydrochloride dose adjustment as follows. Because the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication is used to treat diabetes and has a blood sugar-lowering effect. However, it can rarely cause serious side effects such as lactic acidosis, so caution is required regarding this symptom. Lactic acidosis can manifest as muscle pain, weakness, breathing difficulties, and abdominal pain, and if these symptoms occur, medical consultation should be sought immediately. Additionally, this medication may increase the risk of hypoglycemia when taken with insulin or sulfonylureas, so dosage adjustments may be needed. Patients with impaired kidney function or those with acute infections, dehydration, heart failure, or acute myocardial infarction should not use this medication. In particular, this medication should be temporarily discontinued before and after tests involving iodinated contrast agents, and therapy should be resumed only after kidney function has been confirmed to be normal. It is advisable for pregnant women or those who may become pregnant and patients with liver function disorders to avoid using this medication. During treatment with this medication, urinary or genital infections may occur, and prompt treatment is necessary if symptoms of infection arise. Caution should be taken for elderly patients or those at risk for dehydration regarding fluid loss. Additionally, vitamin B12 levels may decrease, so regular testing is recommended if necessary. Alcohol consumption may increase the risk of lactic acidosis, so drinking alcohol should be avoided. In cases of surgery or severe illness, this medication should be temporarily discontinued and resumed only after the condition stabilizes. This medication should be swallowed whole and not crushed or chewed, although the tablet coating may pass in stool, which is normal. Serious side effects may occur in cases of overdose, so prescribed dosages should be adhered to, and any unusual symptoms should prompt immediate medical attention. Lastly, it should be stored out of reach of children and kept in its original container for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain the storage temperature between 1 to 30 degrees Celsius to preserve the medication's effectiveness and safety.
Dark pink oval sustained-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin L-Proline 31.38mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 15.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 15.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Chong Kun Dang
CombinationEmpagliflozin L-Proline 15.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jonggeun Dang Co., Ltd.
CombinationEmpagliflozin L-Proline 6.28mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 6.28mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 6.28mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 12.55mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.